Bronchoscopy and bleeding risk Felix J.F. Herth Eur Respir Rev, 26 (145) 170052; 10.1183/16000617.0052-2017 | |
Management of antithrombotic agents in patients undergoing flexible bronchoscopy Sami Abuqayyas, Shine Raju, John R. Bartholomew, Roulan Abu Hweij, Atul C. Mehta Eur Respir Rev, 26 (145) 170001; 10.1183/16000617.0001-2017 | |
Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures Vikas Pathak, J. Erin Allender, Mollie W. Grant Eur Respir Rev, 26 (145) 170020; 10.1183/16000617.0020-2017 | |
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Salvatore Corrao, Giuseppe Brunori, Umberto Lupo, Francesco Perticone Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 | |
Nasal high flow therapy: a novel treatment rather than a more expensive oxygen device Eleni Ischaki, Ioannis Pantazopoulos, Spyros Zakynthinos Eur Respir Rev, 26 (145) 170028; 10.1183/16000617.0028-2017 | |
The role of macrophages in interstitial lung diseases Giulio Rossi, Alberto Cavazza, Paolo Spagnolo, Salvatore Bellafiore, Elisabetta Kuhn, Pierpaolo Carassai, Laura Caramanico, Gloria Montanari, Gaia Cappiello, Alessandro Andreani, Francesca Bono, Nazarena Nannini Eur Respir Rev, 26 (145) 170009; 10.1183/16000617.0009-2017 | |
Differential diagnosis of granulomatous lung disease: clues and pitfalls Shinichiro Ohshimo, Josune Guzman, Ulrich Costabel, Francesco Bonella Eur Respir Rev, 26 (145) 170012; 10.1183/16000617.0012-2017 | |
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence Michele R. Schaeffer, Yannick Molgat-Seon, Christopher J. Ryerson, Jordan A. Guenette Eur Respir Rev, 26 (145) 170033; 10.1183/16000617.0033-2017 | |
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence Emily C. Bell, Narelle S. Cox, Nicole Goh, Ian Glaspole, Glen P. Westall, Alice Watson, Anne E. Holland Eur Respir Rev, 26 (145) 170072; 10.1183/16000617.0072-2017 | |
Rare pulmonary diseases: a common fight Sergio Harari, Marc Humbert Eur Respir Rev, 26 (145) 170059; 10.1183/16000617.0059-2017 | |
How I manage pulmonary Langerhans cell histiocytosis Gwenaël Lorillon, Abdellatif Tazi Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017 | |
Heritable pulmonary hypertension: from bench to bedside Barbara Girerd, Jason Weatherald, David Montani, Marc Humbert Eur Respir Rev, 26 (145) 170037; 10.1183/16000617.0037-2017 | |
Clinical care for primary ciliary dyskinesia: current challenges and future directions Bruna Rubbo, Jane S. Lucas Eur Respir Rev, 26 (145) 170023; 10.1183/16000617.0023-2017 | |
The lung in amyloidosis Paolo Milani, Marco Basset, Francesca Russo, Andrea Foli, Giovanni Palladini, Giampaolo Merlini Eur Respir Rev, 26 (145) 170046; 10.1183/16000617.0046-2017 | |
Exertional dyspnoea in pulmonary arterial hypertension Daniel Dumitrescu, Olivier Sitbon, Jason Weatherald, Luke S. Howard Eur Respir Rev, 26 (145) 170039; 10.1183/16000617.0039-2017 | |
Evaluating disease severity in idiopathic pulmonary fibrosis Hasti Robbie, Cécile Daccord, Felix Chua, Anand Devaraj Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 | |
The threat in chronic lung diseases: acute exacerbations Michael Kreuter, Vincent Cottin Eur Respir Rev, 26 (145) 170075; 10.1183/16000617.0075-2017 | |
Personalised medicine: are we ready? Renaud Louis, Nicolas Roche Eur Respir Rev, 26 (145) 170088; 10.1183/16000617.0088-2017 | |
Pulmonary hypertension in systemic sclerosis: different phenotypes David Launay, Vincent Sobanski, Eric Hachulla, Marc Humbert Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 | |
New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis Olga Torre, Davide Elia, Antonella Caminati, Sergio Harari Eur Respir Rev, 26 (145) 170042; 10.1183/16000617.0042-2017 | |
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Ganesh Raghu Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 | |
Severe idiopathic pulmonary fibrosis: what can be done? Antonella Caminati, Roberto Cassandro, Olga Torre, Sergio Harari Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017 | |
When to start and when to stop antifibrotic therapies Sebastiano Emanuele Torrisi, Mauro Pavone, Ada Vancheri, Carlo Vancheri Eur Respir Rev, 26 (145) 170053; 10.1183/16000617.0053-2017 | |
Systems medicine advances in interstitial lung disease Flavia R. Greiffo, Oliver Eickelberg, Isis E. Fernandez Eur Respir Rev, 26 (145) 170021; 10.1183/16000617.0021-2017 | |
Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis Yasuhiro Kondoh, Vincent Cottin, Kevin K. Brown Eur Respir Rev, 26 (145) 170050; 10.1183/16000617.0050-2017 | |
Personalised medicine in asthma: time for action Kian Fan Chung Eur Respir Rev, 26 (145) 170064; 10.1183/16000617.0064-2017 | |